Live Oak Allergy Shots (SCIT)
Live oak (Quercus virginiana) is the most under-characterized major oak allergen in the US — the only evergreen oak with clinical prominence across the Gulf coast (VA to TX), with a uniquely early February–April pollen season and zero formally named WHO/IUIS allergens as of May 2026.
Live Oak Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to live oak — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of live oak allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of live oak immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of live oak extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for live oak allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing live oak extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription live oak immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat live oak allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Live Oak?
The biology, taxonomy, and clinical fingerprint of Live Oak — the foundation of how SCIT targets it.
Live oak — Quercus virginiana — is the iconic Spanish-moss-draped evergreen of the Gulf coast, releasing massive quantities of pollen from February through April in coastal cities from Houston to Charleston. Despite being among the most clinically significant tree allergens in the region, it has no formally named WHO/IUIS allergen as of May 2026.
- Scientific name
- Quercus virginiana Mill.
- Family
- FagaceaeBeech family
- Type
- Evergreen tree pollen (the only major evergreen US oak)
- Native to
- Coastal southeastern US — Virginia to Florida to Texas (USDA PLANTS); the most clinically prominent oak across the Gulf states
- Allergen proteins
- No IUIS-named allergen for Quercus virginiana as of May 2026 — a significant evidence gap given the species' enormous clinical relevance across the Gulf coastCross-reactivity to Que a 1 (white oak PR-10, ~17 kDa) is inferred from genus-level Quercus molecular homology — but has not been directly characterized for Q. virginiana pollenProfilin and Ca-binding protein expression are assumed by analogy with other Quercus species but not specifically named at WHO/IUIS for this species
- Particle size
- 25–35 μm
- Avoidance difficulty
- Nearly impossible
How Live Oak Allergy Presents
Symptoms by body system — useful for distinguishing Live Oak sensitivity from overlapping allergies and infections.
Respiratory
- Sneezing and nasal discharge beginning in February in Houston, New Orleans, Mobile, and Savannah — the earliest spring tree pollen in these cities
- Nasal congestion during daily counts exceeding 1,000 grains per cubic meter in Gulf-coast cities at peak
- Itchy, swollen nasal passages persisting through the 8–10 week Gulf-coast live oak season
- Allergic asthma exacerbations — wheezing and chest tightness in sensitized asthmatic patients during February–April peak
- Post-nasal drip and chronic throat clearing from sustained high-pollen exposure
Ocular
- Intense bilateral eye itching and watering during the February–April live oak season
- Conjunctival redness and swelling on high-pollen days
- Morning eyelid puffiness from overnight pollen settling
- Photophobia during severe allergic conjunctivitis episodes in peak pollen weeks
Dermal
- Oral allergy syndrome (OAS) to raw apple, hazelnut kernel, or peach is possible via inferred Que a 1 / Bet v 1 PR-10 cross-reactivity — but OAS is considerably less documented for live oak than for white oak or birch, and should be confirmed by component testing rather than assumed
- Contact urticaria from direct pollen contact in highly sensitized individuals
- Atopic dermatitis flares coinciding with the February–April Gulf-coast live oak peak in susceptible patients
Systemic
- Fatigue from an allergy season that begins in mid-winter when most patients aren't expecting spring allergies
- Sleep disruption from nighttime nasal congestion during peak February–March weeks
- Confusion about whether symptoms are 'cedar fever,' 'early spring pollen,' or live oak — all of which can overlap in the Gulf states
- Reduced quality of life during the early spring outdoor season in one of America's most pleasant outdoor-living climates
Live oak is the most under-characterized oak in the US — no named WHO/IUIS allergen, no dedicated SCIT trial — but in my Charleston practice I see more live-oak-driven February rhinitis than every other tree combined. We treat it with a Quercus-anchored mix and lean on the Itulazax TT-04 family data for the immunologic rationale, because that's the best evidence we have.
When & Where Live Oak Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: February–March along the Gulf coast; as early as late January in southern Florida and Houston· ~8–10 weeks — the longest and earliest pollen season of any US oak; later-starting than mountain cedar but earlier than all deciduous oaks
US Exposure Map
7 high-intensity statesWhat Live Oak Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Live oak has no formally named WHO/IUIS allergen as of May 2026, so cross-reactivity data are inferred from genus-level Quercus molecular homology rather than directly characterized Q. virginiana pollen proteins. The Jeong 2016 inhibition data (white oak extract inhibits 77.4–81.5% of Bet v 1 IgE binding) apply to Q. alba and are extrapolated to Q. virginiana by analogy.
Within-genus Quercus; cross-reactivity inferred from Que a 1 genus-level homology — no direct Q. virginiana data
Q. alba has the only named US Quercus allergen (Que a 1); live oak cross-reactivity inferred
Fagales PR-10 cross-reactivity inferred via Que a 1 / Bet v 1 homology — not directly characterized for live oak
Birch SCIT oak-season cross-protection confirmed for Q. alba in Itulazax TT-04; extrapolated to live oak
PR-10 OAS via inferred Que a 1 / Mal d 1 cross-reactivity — less documented for live oak than for white oak or birch
Live Oak PR-10 OAS — Inferred, Not Directly Characterized
Oral allergy syndrome to raw apple, hazelnut kernel, and peach via PR-10 cross-reactivity is well-documented for white oak (Que a 1) and birch (Bet v 1). For live oak specifically, OAS is inferred from genus-level homology but has not been formally characterized in published molecular studies. If you experience OAS symptoms during or after live oak season, a board-certified allergist should confirm whether the primary sensitizer is Q. virginiana, Q. alba, or birch Bet v 1 via component-resolved testing before attributing food reactions specifically to live oak.
Is SCIT Right for Your Live Oak Allergy?
Answer five questions to assess whether live oak SCIT or a Fagales-anchored approach is appropriate for your Gulf-coast winter allergy.
How severe are your Gulf-coast February–April allergy symptoms during live oak season?
The Live Oak SCIT Protocol
Live oak SCIT uses non-standardized Quercus extract (often Q. alba or Q. virginiana-labeled extract depending on manufacturer) in a conventional build-up and maintenance ladder. Gulf-coast patients should initiate build-up in summer or fall to reach protective doses before the February live oak season.
Injections begin at 1:10,000 w/v and increase incrementally. Gulf-coast patients face an unusually early allergy season (February) — summer or fall build-up initiation is strongly preferred to minimize the reactivity increase from active live oak pollen co-exposure during titration. Mandatory 30-minute post-injection observation at every visit.
Monthly maintenance sustains Quercus-species cross-reactive tolerance inferred from Que a 1 / Bet v 1 PR-10 homology. The Itulazax TT-04 oak-season secondary endpoint confirms that Bet v 1-targeted immunotherapy produces meaningful oak-season symptom reduction — providing family-level evidence applicable to live oak by genus-level extrapolation.
Lasting benefit of 7–12+ years is expected with full course completion. Gulf-coast live oak seasons are early and prolonged — completing the full course is essential for durable benefit.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Live Oak SCIT
Live oak has no species-specific SCIT RCT and no formally named WHO/IUIS allergen — it is the most clinically prominent US oak without dedicated molecular or immunotherapy evidence. All efficacy estimates for live oak SCIT derive from the Quercus genus-level evidence base, extrapolated via inferred Que a 1 homology.
- Oak-season cross-protection (Quercus genus-level; birch-homologous immunotherapy)60%Itulazax TT-04 secondary endpoint — oak season; ALK/EMA 2019, N=634 birch-sensitized adults (extrapolated to live oak by genus analogy)
- Bet v 1 IgE inhibition by Quercus extract (white oak — closest characterized species)79%Jeong et al., J Korean Med Sci 2016 — Q. alba extract; extrapolated to Q. virginiana by genus-level homology
No SCIT RCT exists for Q. virginiana, and no IUIS-named allergen has been characterized in live oak pollen. This is the most significant evidence gap among clinically prominent US tree allergens. All efficacy estimates for live oak SCIT are extrapolated from white oak (Que a 1) and birch (Bet v 1) data using genus-level cross-reactivity assumptions. Board-certified allergists treating Gulf-coast patients with live oak allergy use Quercus-anchored mixes and accept this extrapolation as the best available standard of care, per AAAAI Practice Parameter (Greenhawt 2023) guidance on family-level immunotherapy.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Live Oak SCIT Side Effects
Live oak SCIT side effects follow the standard inhalant SCIT profile. Gulf-coast patients should initiate build-up in summer or fall — starting build-up during the February–April live oak season significantly increases reactivity risk at each dose increment.
Local reactions
4 documentedSystemic reactions
4 documentedA 30-minute post-injection observation accompanies every live oak SCIT dose, whether given in a clinic or self-administered at home with Curex — where the first dose and any dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand. Gulf-coast patients should plan their build-up schedule around the early February pollen release — ideally starting 6–9 months before the season. Active uncontrolled asthma should be stabilized before initiating SCIT.
SCIT vs Alternatives for Live Oak
Gulf-coast live-oak-allergic patients have four main options: Quercus-anchored SCIT (using genus-level cross-protection) — now self-administered as a weekly at-home shot with Curex — sublingual drops, avoidance strategies (difficult given live oak's ubiquity across Gulf-coast cities), and daily seasonal medications.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Moderate-High — Quercus genus-level evidence via Itulazax TT-04 oak-season endpoint; no live-oak-specific RCT | Moderate — no FDA-approved live oak SLIT tablet; off-label Quercus drops available | Low — live oak is the dominant landscape tree across Gulf-coast cities; avoidance is impractical | Moderate — antihistamines + nasal corticosteroids for mild-to-moderate symptoms |
| 5-yr cost | $3,500–$15,000 over 5 years | Varies by provider; sublingual drops are a general allergy modality, not Curex's product | Low — HEPA, pollen masks, windows closed in February–April | $500–$2,000 over 5 years |
| Duration | 3–5 year course | 3–5 year course | Indefinite — no tolerance change | Indefinite — seasonal use every year |
| Convenience | At-home weekly self-injection with Curex; summer/fall start preferred for Gulf-coast patients; first dose and dose changes supervised live over Zoom | Daily at-home — particularly valuable for patients unable to reach clinics in winter | High inconvenience during prime winter-spring outdoor season | High convenience |
| Safety | Excellent — your live oak serum is USP <797> sterile-compounded, the prescribing physician supervises every dose change over Zoom, a prescribed epinephrine auto-injector is on hand, and a 30-minute self-observation follows | Favorable — no systemic anaphylaxis in EU SLIT trials | Safe | Generally safe |
| Lasting effect | 7–12+ years after completion | Emerging — less durability data vs SCIT | None — symptoms return each February | None — must take every season |
SCITBest
SLIT
Avoidance
Medications
SCIT anchored to the Quercus genus is the best available option for lasting live oak allergy relief — using genus-level cross-protection evidence since no live-oak-specific RCT exists — and with Curex, eligible Gulf-coast patients self-administer that shot at home for $129/month instead of accessing weekly clinic visits, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand.
What Live Oak SCIT Actually Costs
Live oak SCIT is covered by most major US insurers under standard allergy immunotherapy benefits when prescribed by a board-certified allergist with a positive skin test or specific IgE for Quercus species. Because Que a 1 (white oak) is the reference IUIS allergen for the genus, component testing may be documented as Que a 1 sensitization even when treating live oak patients. Pre-authorization is recommended. Curex at-home IgE testing identifies specific live oak sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your live oak allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Live Oak SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
In the Gulf coast states — Texas, Louisiana, Mississippi, Alabama, Georgia, South Carolina, and Florida — live oak (Quercus virginiana) begins releasing pollen as early as late January, often peaking through February and March. This is unique among US oaks: most deciduous oaks wait until March or April, but live oak's evergreen habit allows it to develop catkins throughout the winter and release pollen as soon as temperatures rise slightly. In cities like Houston, New Orleans, and Charleston, February live oak pollen can reach counts exceeding 1,000 grains per cubic meter — triggering rhinitis, conjunctivitis, and asthma exacerbations weeks before most patients expect 'spring' allergies.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.